BeOne Medicines

BeOne Resolves AbbVie Patent Dispute as Brukinsa Powers First Profit and Swiss Rebrand

BeOne,, formerly BeiGene, resolves AbbVie’s patent dispute over Brukinsa®, achieves first-ever quarterly profit, and finalizes Swiss rebrand, signaling its evolution from China-based biotech to global oncology player.

Best-in-class vs first-in-class

Zanubrutinib Surpasses Ibrutinib: A Case Study in Best-in-Class Innovation

BeOne Medicines is reshaping hematology with zanubrutinib. Superior efficacy, cleaner safety, and strong market momentum put it ahead of ibrutinib — a textbook case of best-in-class drugs eclipsing first-in-class pioneers.

BeOne Medicines

BeOne Medicines Sells IMDELLTRA® Ex-China Royalties to Royalty Pharma for $885M Upfront

In a strategic move, BeOne monetizes its ex-China royalty stream for the DLL3×CD3 bispecific IMDELLTRA®, freeing capital for its pipeline while retaining domestic commercialization rights.